Westborg Inger, Granstam Elisabet, Rosso Aldana, Albrecht Susanne, Karlsson Niklas, Lövestam-Adrian Monica
Department of Clinical Sciences, Umeå University Hospital, Umeå, Sweden.
Centre for Clinical Research, Uppsala University, County Council of Västmanland, Västerås, Sweden.
Acta Ophthalmol. 2017 Dec;95(8):787-795. doi: 10.1111/aos.13539. Epub 2017 Aug 21.
To present Swedish Macula Register (SMR) data regarding treatment of neovascular age-related macular degeneration (AMD) in clinical practice since 2008.
A retrospective register-based study was conducted. Evaluation of baseline demographics, visual outcome and number of injections during this period is presented.
Mean age at diagnosis was 79 ± (SD) 8 years; 65% were female. The proportion of patients with <2 months' duration of symptoms increased from 26% in 2008 to 41% in 2014 (p = 0.001). Mean visual acuity (VA) at baseline increased from 54.3 ± 15.0 early treatment diabetic retinopathy study (ETDRS) letters in 2008 to 57.8 ± 15.6 letters in 2014 (CI 2.6; 4.3; p < 0.001). Mean VA after 1 year of treatment increased from 57.8 ± 17.7 ETDRS letters for patients who started the treatment in 2008 to 62.8 ± 16.4 ETDRS letters in patients starting treatment in 2014 (CI 2.67; 4.64; p < 0.001). During all study years, the proportion of patients with an improvement in VA of between 5 and 15 letters was around 30%, while 14% had VA improvement of more than 15 letters. The mean number of injections during the first treatment year increased from 4.3 ± 1.9 in 2008 to 5.9 ± 2.9 in 2014 (CI 1.40; 1.67; p < 0.001). Seven-year follow-up of 322 eyes showed a mean change of -1 letters from baseline, with a mean of 21 injections for the entire period.
The duration of symptoms before treatment decreased, while VA at baseline and after 1 year of treatment increased over the years and so did the number of injections. Long-term follow-up demonstrated stable VA.
呈现自2008年以来瑞典黄斑登记处（SMR）关于临床实践中新生血管性年龄相关性黄斑变性（AMD）治疗的数据。
进行了一项基于登记处的回顾性研究。介绍了在此期间对基线人口统计学、视力结果和注射次数的评估。
诊断时的平均年龄为79±（标准差）8岁；65%为女性。症状持续时间<2个月的患者比例从2008年的26%增加到2014年的41%（p = 0.001）。基线时的平均视力（VA）从2008年的54.3±15.0早期治疗糖尿病性视网膜病变研究（ETDRS）字母增加到2014年的57.8±15.6字母（置信区间2.6；4.3；p < 0.001）。治疗1年后的平均VA从2008年开始治疗的患者的57.8±17.7 ETDRS字母增加到2014年开始治疗的患者的62.8±16.4 ETDRS字母（置信区间2.67；4.64；p < 0.001）。在所有研究年份中，视力提高5至15个字母的患者比例约为30%，而14%的患者视力提高超过15个字母。第一个治疗年度的平均注射次数从2008年的4.3±1.9次增加到2对322只眼睛进行的7年随访显示，与基线相比平均变化为-1个字母，整个期间平均注射21次。
治疗前症状持续时间缩短，而多年来基线时和治疗1年后的视力均有所提高，注射次数也增加了。长期随访显示视力稳定。
